BioMedNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Partners with Navix Health to Provide Next-Generation Digital Healthcare Platform

SOBRSafe (NASDAQ: SOBR), a company that is pioneering noninvasive, humane and hygienic alcohol detection with a priority on safety, support and accountability, has been selected by Navix Health, a leading provider of innovative healthcare technologies, as its exclusive alcohol data partner. According to the announcement, Navix Health will integrate SOBRsafe’s advanced alcohol monitoring technology into its proprietary Navix Hub(TM). The exclusive hub is a fully unified facility and practice management software for behavioral health. The integration of the SOBRsafe technology, which will enable Navix Hub users to augment current operations with touch-based alcohol monitoring, is aimed to enhance patient care, increase compliance and promote better health outcomes. According to the two companies, the collaboration “marks a significant milestone in advancing digital health and bolstering patient-centric care.” The new partnership combines each company’s expertise to provide comprehensive digital health solutions that are designed to meet the evolving needs of patients, healthcare providers, and stakeholders in the healthcare space. Navix Health specializes in seamless behavioral health software that streamlines provider experiences and improves facility management. “At SOBRsafe, it is our goal to empower positive outcomes,” said SOBRSafe chair and CEO Dave Gandini in the press release. “In this we are wholly aligned with Navix Health, and we believe the integration with Navix Hub positions both our organizations to create maximum benefit through actionable alcohol intelligence. We are excited to partner with Navix health, and we look forward to providing value to their customers industrywide.”

To view the full press release, visit https://ibn.fm/XZyWv

About SOBR Safe Inc. 

SOBRsafe is pioneering noninvasive, humane and hygienic alcohol detection with a priority on safety, support and accountability. The company’s advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. With a powerful back-end data platform, SOBRsafe provides next-generation, passive detection technology for behavioral health. For more information about SOBRsafe, visit www.SOBRsafe.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

1 day ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform…

4 days ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13 

HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold…

5 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations…

5 days ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Granted 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

6 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received…

1 week ago